Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2006 Nov;98(11):1779–1782.

Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders.

Ranju Gupta 1, Sirisha Perumandla 1, Yelena Patsiornik 1, Selvanayagam Niranjan 1, Anju Ohri 1
PMCID: PMC2569799  PMID: 17128687

Abstract

STUDY OBJECTIVE: To assess the incidence of pulmonary hypertension (PH) in patients with chronic myeloproliferative disorders (CMPD). METHOD: Twenty-seven patients with a diagnosis of CMPD were included in the study. Patients were excluded if they had a secondary cause of PH. Diagnosis of PH was established if right ventricular systolic pressure (RVSP) by transthoracic echocardiography (TTE) was >35 mmHg. RESULTS: Diagnosis of PH was established in 14 out of 27 patients. Two patients were excluded from analysis because of poor ejection fraction on TTE, resulting in a final diagnosis of PH in 12 of 25 (48%) patients. Of these 25 patients, seven of nine with essential thrombocytosis (ET), five of 14 with polycythemia vera (PV), and 0 out of two with chronic myeloid leukemia (CML) had PH. All patients were asymptomatic at the time of their most recent visit. There was no relationship between PH and age at diagnosis, duration of disease, platelet count and hematocrit at diagnosis or during follow-up, both for the entire cohort or for specific diagnosis of ET or PV. CONCLUSION: Pulmonary hypertension appears to be common in patients with CMPD. Further studies are needed to evaluate the impact of treatment on PH and long-term survival in these patients.

Full text

PDF
1779

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dingli D., Utz J. P., Krowka M. J., Oberg A. L., Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest. 2001 Sep;120(3):801–808. doi: 10.1378/chest.120.3.801. [DOI] [PubMed] [Google Scholar]
  2. Einsfelder B. M., Müller K-M. Pulmonale Hypertonie bei chronischen myeloproliferativen Erkrankungen. Pathologe. 2005 May;26(3):169–177. doi: 10.1007/s00292-004-0709-2. [DOI] [PubMed] [Google Scholar]
  3. García-Manero G., Schuster S. J., Patrick H., Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol. 1999 Feb;60(2):130–135. doi: 10.1002/(sici)1096-8652(199902)60:2<130::aid-ajh8>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  4. Garypidou Vasilia, Vakalopoulou Sofia, Dimitriadis Dimokritos, Tziomalos Konstantinos, Sfikas George, Perifanis Vasilios. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. Haematologica. 2004 Feb;89(2):245–246. [PubMed] [Google Scholar]
  5. Haznedaroğlu Ibrahim C., Atalar Enver, Oztürk M. Akif, Ozer Necla, Ovünç Kenan, Aksöyek Serdar, Kes Sirri, Kirazli Serafettin, Ozmen Ferhan. Thrombopoietin inside the pulmonary vessels in patients with and without pulmonary hypertension. Platelets. 2002 Nov;13(7):395–399. doi: 10.1080/0953710021000024000. [DOI] [PubMed] [Google Scholar]
  6. Kadikoylu Gurhan, Onbasili Alper, Tekten Tarkan, Barutca Sabri, Bolaman Zahit. Functional and morphological cardiac changes in myeloproliferative disorders (clinical study). Int J Cardiol. 2004 Nov;97(2):213–220. doi: 10.1016/j.ijcard.2003.08.013. [DOI] [PubMed] [Google Scholar]
  7. Martin-Duran R., Larman M., Trugeda A., Vazquez de Prada J. A., Ruano J., Torres A., Figueroa A., Pajaron A., Nistal F. Comparison of Doppler-determined elevated pulmonary arterial pressure with pressure measured at cardiac catheterization. Am J Cardiol. 1986 Apr 1;57(10):859–863. doi: 10.1016/0002-9149(86)90627-2. [DOI] [PubMed] [Google Scholar]
  8. Marvin K. S., Spellberg R. D. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. Chest. 1993 Feb;103(2):642–644. doi: 10.1378/chest.103.2.642. [DOI] [PubMed] [Google Scholar]
  9. Padma-Nathan H., Hellstrom W. J., Kaiser F. E., Labasky R. F., Lue T. F., Nolten W. E., Norwood P. C., Peterson C. A., Shabsigh R., Tam P. Y. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997 Jan 2;336(1):1–7. doi: 10.1056/NEJM199701023360101. [DOI] [PubMed] [Google Scholar]
  10. Reisner S. A., Rinkevich D., Markiewicz W., Tatarsky I., Brenner B. Cardiac involvement in patients with myeloproliferative disorders. Am J Med. 1992 Nov;93(5):498–504. doi: 10.1016/0002-9343(92)90576-w. [DOI] [PubMed] [Google Scholar]
  11. Rostagno C., Prisco D., Abbate R., Poggesi L. Pulmonary hypertension associated with long-standing thrombocytosis. Chest. 1991 May;99(5):1303–1305. doi: 10.1378/chest.99.5.1303. [DOI] [PubMed] [Google Scholar]
  12. Rubin L. J. Primary pulmonary hypertension. Chest. 1993 Jul;104(1):236–250. doi: 10.1378/chest.104.1.236. [DOI] [PubMed] [Google Scholar]
  13. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000 Apr 27;342(17):1255–1265. doi: 10.1056/NEJM200004273421706. [DOI] [PubMed] [Google Scholar]
  14. Tefferi A., Silverstein M. N., Hoagland H. C. Primary thrombocythemia. Semin Oncol. 1995 Aug;22(4):334–340. [PubMed] [Google Scholar]
  15. Tefferi Ayalew. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc. 2003 Feb;78(2):174–194. doi: 10.4065/78.2.174. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES